Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

ClinicalTrials.gov ID: NCT02915744

Public ClinicalTrials.gov record NCT02915744. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 1:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Study identification

NCT ID
NCT02915744
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Nektar Therapeutics
Industry
Enrollment
178 participants

Conditions and interventions

Interventions

  • Docetaxel Drug
  • Eribulin Drug
  • Gemcitabine Drug
  • Ixabepilone Drug
  • NKTR-102 Drug
  • Nab-paclitaxel Drug
  • Paclitaxel Drug
  • Vinorelbine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2016
Primary completion
Jun 30, 2020
Completion
Jun 30, 2020
Last update posted
Apr 13, 2023

2016 – 2020

United States locations

U.S. sites
19
U.S. states
15
U.S. cities
19
Facility City State ZIP Site status
Investigator Site - Tucson Tucson Arizona 85724
Investigator Site - Orange Orange California 92868
Investigator Site - San Francisco San Francisco California 94115
Investigator Site - Miami Miami Florida 33136
Investigator Site - Plantation Plantation Florida 33324
Investigator Site - West Palm Beach West Palm Beach Florida 33401
Investigator Site - Athens Athens Georgia 30607
Investigator Site - Baltimore Baltimore Maryland 21201
Investigator Site - Boston Boston Massachusetts 02115
Investigator Site - Minneapolis Minneapolis Minnesota 55455
Investigator Site - Saint Louis St Louis Missouri 63110
Investigator Site - New York New York New York 10065
Investigator Site - Chapel Hill Chapel Hill North Carolina 27599
Investigator Site - Columbus Columbus Ohio 43210
Investigator Site - Germantown Germantown Tennessee 38138
Investigator Site - Fort Worth Fort Worth Texas 76104
Investigator Site - Houston Houston Texas 77030
Investigator Site - Salt Lake City Salt Lake City Utah 84106
Investigator Site - Seattle Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02915744, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 13, 2023 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02915744 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →